Introduction {#S1}
============

Common variable immunodeficiency (CVID) is the most prevalent symptomatic primary immunodeficiency ([@B1]). It is characterized by hypogammaglobulinemia and an impaired antibody response leading to recurrent and chronic infections ([@B2]). On the other hand, a significant amount of patients manifest with autoimmunity. Specifically, autoimmune thrombocytopenia (AITP) is commonly seen in patients with CVID with an incidence of up to 14% ([@B3], [@B4]). Intravenous immunoglobulin (IVIG) is being used as a replacement therapy \[immunoglobulin replacement therapy (IGRT)\] for CVID. However, IVIG can also be used at high doses for the treatment of AITP. It is thought that maintenance IGRT might reduce or even prevent recurrent bouts of AITP. Currently, immunoglobulins are increasingly applied subcutaneously in patients with CVID, as there are fewer systemic side effects compared to intravenous applications and it seems to improve the patients' quality of life ([@B5], [@B6]).

Therefore, the objective of this study was to answer the question: Is it safe to switch patients with CVID and AITP from IVIG to subcutaneous immunoglobulin (SCIG) treatment, with respect to the prevention of clinically relevant thrombocytopenia?

Materials and Methods {#S2}
=====================

Patients with both CVID, based on the European Society for Immunodeficiencies criteria, and clinically relevant AITP were included in this cohort study. This retrospective study covered 5 years of chart reviews between 2011 and 2015. Patients were recruited at the Center for Chronic Immunodeficiency in Freiburg, Germany and at the Royal Free Hospital, London, UK. Information on immunological findings, clinical manifestations, and immunoglobulin replacement therapy was collected.

The primary study endpoint was a severe thrombocytopenic event, defined as a platelet count of \<50,000/μl if bleeding episodes occurred, or a platelet count of \<20,000/μl without bleeding. To investigate the incidence of thrombocytopenic events in each group (IVIG vs. SCIG), we retrospectively reviewed participants' platelet counts over a period of 5 years.

We estimated the frequency of thrombocytopenic events by summing up all 6-month periods, in which patients had at least one documented thrombocytopenic event, since the majority of participants had a routine blood draw every 6 months and additionally when bleeding events (including petechial) occurred.

Differences between groups were analyzed using the non-parametric Chi-square test and Mann--Whitney *U*-test. Results are illustrated using bar charts or box plot diagrams; with boxes representing the lower quartile, the median and the upper quartile, while the whiskers show the 10th and 90th percentiles. A Kaplan--Meier analysis was performed to evaluate the occurrence of primary study endpoint. The Kaplan--Meier curves were compared using log-rank test. Data were analyzed using GraphPad Prism version 7.01 (GraphPad Software, USA). *p* \< 0.05 was considered significant.

Written consent was obtained of all patients. This retrospective study was performed in accordance with the ethical standards of the Helsinki declaration and was approved by the institutional review boards of the two hospitals. Ethics protocol No. 295/13 from the University Hospital of the Albert Ludwigs University, Freiburg; and No. 04/Q0501/119 for the Royal Free Hospital, University College London, Institute of Immunity and Transplantation, London, UK.

Results {#S3}
=======

This retrospective cohort study recruited 61 adult patients between 19 and 71 years of age who had a diagnosis of CVID and at least one event of clinical significant thrombocytopenia at any time during their medical history. Forty-two patients were enrolled at the Center for Chronic Immunodeficiency in Freiburg, Germany, and 19 patients were recruited at the Royal Free Hospital in London, UK. All participants were on a stable dose of IgG replacement (there was no more variation than 10%), with a median of 477.5 mg/kg/month (range: 232--942), and a target trough level of \>7g/l. Thirty patients received immunoglobulin through the intravenous route (IVIG), and 31 patients were on subcutaneous immunoglobulin (SCIG) replacement.

Two patients changed from IVIG to SCIG during the observation period. They were documented in the IVIG cohort until the date of switching and included in the SCIG cohort 3 months after switching from IVIG to SCIG. No patient switched from SCIG to IVIG. Participants had platelet counts and IgG trough levels determined at least every 6-month, and additionally during bleeding episodes (Table [1](#T1){ref-type="table"}). Trough levels used for the analysis represent the average level among measurements.

###### 

Patient demographics and disease characteristics.

  ID   Age range   IgG replacement   IgG dose (g/month)   IgG level[^a^](#tfn1){ref-type="table-fn"} (g/L)   Median thrombocytes (Tsd/μl)   Immunomodulation         Other disorders
  ---- ----------- ----------------- -------------------- -------------------------------------------------- ------------------------------ ------------------------ ---------------------------------------------------------------
  1    36--40      IV                20                   9.83                                               312                            No                       Splenomegaly
  2    46--50      IV                90                   10.9                                               189                            Rituximab                Splenomegaly, AIN
  3    31--35      IV                120                  10.5                                               151                            Rituximab                Splenomegaly
  4    51--55      IV                25                   **15.8**                                           **25**                         No                       Splenectomy, lymphoma
  5    21--25      SC                25                   **3.9**                                            **25**                         No                       Splenomegaly
  6    21--25      IV                20                   4.3                                                211                            Steroids                 Splenomegaly, AIN
  7    51--55      IV                20                   8.2                                                134                            Steroids                 Splenomegaly
  8    51--55      SC                20                   8.8                                                200                            No                       Splenomegaly
  9    21--25      IV                20                   **5.7**                                            **25.6**                       Steroids                 Splenectomy
  10   51--55      SC                25                   **8.8**                                            **45.1**                       Steroids                 None
  11   36--40      IV                20                   8                                                  145                            No                       Splenectomy
  12   41--45      SC                32                   6.1                                                250                            Steroids                 Splenomegaly
  13   51--55      SC                45                   10                                                 107                            Steroids                 Splenomegaly
  14   51--55      SC                33                   7.0                                                140                            Steroids                 Splenomegaly
  15   56--60      SC                20                   5.1                                                136                            No                       Splenomegaly
  16   51--55      SC                64                   8.7                                                257                            No                       Splenomegaly
  17   41--45      SC                30                   9.2                                                158                            Steroids                 Splenomegaly
  18   36--40      SC                25                   9.8                                                181                            No                       Psoriasis
  19   26--30      SC                28                   **7.5**                                            **28**                         Steroids                 Splenomegaly
  20   51--55      IV                20                   **9.8**                                            **20**                         Methotrexate, steroids   Splenomegaly, rheumatoid arthritis, antiphospholipid syndrome
  21   51--55      SC                50                   9.4                                                147                            Rituximab                Splenomegaly
  22   41--45      SC                38                   **7.8**                                            **38**                         Steroids                 Splenomegaly
  23   26--30      IV                45                   15.6                                               97                             Steroids                 Splenomegaly
  24   46--50      SC                51                   10.9                                               60                             Steroids                 Splenomegaly
  25   46--50      SC                30                   6.1                                                300                            No                       Splenectomy
  26   41--45      SC                64                   8.4                                                75                             No                       Splenomegaly
  27   61--65      SC                20                   **8.7**                                            **20**                         No                       Splenomegaly
  28   51--55      IV                38                   **11.2**                                           **38**                         No                       Splenomegaly
  29   41--45      SC                38                   9.4                                                114                            Steroids, ciclosporin    Splenomegaly, autoimmune enteropathy, vitiligo
  30   21--25      SC                35                   8.1                                                205                            No                       Splenomegaly
  31   36--40      SC                20                   **8.7**                                            **12.8**                       No                       None
  32   21--25      SC                40                   7.0                                                126                            No                       Splenomegaly
  33   31--35      IV                20                   9.6                                                175                            No                       Splenectomy
  34   61--65      SC                36                   **9.5**                                            **36**                         Rituximab                Splenomegaly
  35   41--45      SC                40                   12.0                                               170                            Steroids                 Splenomegaly
  36   56--60      IV                28                   9.8                                                177                            No                       Celiac disease
  37   36--40      SC                53                   7.1                                                84                             Rituximab                Splenomegaly
  38   21--25      IV                20                   **5.9**                                            **80**                         No                       Splenectomy
  39   26--30      IV                20                   10.6                                               152                            No                       Splenomegaly
  40   31--35      IV                20                   **8.7**                                            **20**                         No                       Splenomegaly
  41   66--70      IV                25                   10.8                                               160                            No                       Splenomegaly
  42   26--30      SC                20                   **6.4**                                            **20**                         No                       Splenomegaly
  43   36--40      SC                30                   12.7                                               220                            Rituximab                Splenectomy
  44   61--65      IV                40                   9.8                                                305                            No                       None
  45   46--50      IV                30                   8.4                                                220                            No                       None
  46   51--55      IV                50                   8.8                                                146                            Rituximab                AIHA
  47   31--35      SC                40                   8.2                                                175                            No                       None
  48   31--35      IV                30                   13.5                                               158                            Rituximab                AIN
  49   21--25      IV                35                   8.0                                                442                            Rituximab                Splenectomy
  50   61--65      IV                40                   14.8                                               253                            No                       Splenectomy
  51   36--40      SC                30                   9.4                                                182                            No                       None
  52   71--75      IV                30                   **13**                                             **11.2**                       Rituximab                Splenectomy
  53   36--40      IV                35                   5.2                                                141                            No                       None
  54   46--50      IV                40                   11.2                                               132                            Rituximab                None
  55   51--55      IV                30                   **7.9**                                            **8.6**                        No                       None
  56   51--55      SC                20                   11.2                                               308                            No                       None
  57   31--35      IV                30                   16.3                                               169                            No                       None
  58   41--45      IV                30                   7.9                                                131                            No                       None
  59   36--40      SC                30                   8.6                                                233                            No                       Splenectomy
  60   16--20      SC                30                   10.2                                               150                            No                       None
  61   56--60      IV                25                   10.7                                               253                            No                       Splenectomy

*IV, intravenous; SC, subcutaneous; AIHA, autoimmune hemolytic anemia; AIN, autoimmune neutropenia*.

*^a^IgG levels under replacement therapy*.

*Bold numbers indicate patients with autoimmune thrombocytopenia*.

Reviewing the patients'platelet counts and patient-charts over the last 5 years, we counted eight patients in the SCIG-group, and eight patients in the IVIG-group, which were affected by thrombocytopenic events. However, one patient of the IVIG-group had to be excluded, since his thrombocytopenic events were directly related to chemotherapy he had been receiving because of a diffuse large B-cell lymphoma. All other thrombocytopenic events were classified as AITP.

Patients with AITP under IVIG substitution had infusions scheduled every four weeks; five of them had about of AITP during the third week after infusion. SCIG patients with AITP had their infusions scheduled as follows: six patients had one infusion per week; one patient had injections three times a week, and one individual had infusions every 10 days.

There were no statistically significant correlations between gender (*p* = 0.3248) and thrombocytopenic events. When comparing Ig replacement, there were no significant differences in the occurrence of thrombocytopenia between the IVIG and SCIG-group (Figure [1](#F1){ref-type="fig"}). We, therefore, concluded that CVID patients who received subcutaneously immunoglobulin treatment were not more susceptible to recurrent thrombocytopenic events than CVID patients on IVIG substitution. Moreover, we excluded steroid treatment and splenectomy as confounding factors as we did not observe a significant difference when comparing AITP patients on IVIG or SCIG (Figures [2](#F2){ref-type="fig"}A,B).

![Common variable immunodeficiency (CVID) patients with autoimmune thrombocytopenia on replacement therapy. Kaplan--Meier curves showing the occurrence of thrombocytopenic events in patients receiving subcutaneous immunoglobulin (SCIG) and intravenous immunoglobulin (IVIG). Log-rank test was used to analyze difference between groups. No differences were observed (*p* = 0.528).](fimmu-09-01656-g001){#F1}

![Comparison between immunoglobulin replacement therapy (IGRT) and potential confounding factors in the occurrence of autoimmune thrombocytopenia (AITP) bouts. Data are expressed as the number of patients with AITP bouts receiving IGRT (the total is 14). Chi-squared was used. **(A)** No difference was observed when comparing patients receiving steroids or other immunomodulatory treatment *p* = 0.5692. **(B)** Status of splenectomy made no difference in the occurrence of thrombocytopenic events *p* = 0.0769.](fimmu-09-01656-g002){#F2}

Comparing IgG trough levels, we again found no difference between patients in the IVIG-group and the SCIG-group (*p* = 0.4634) (Figure [3](#F3){ref-type="fig"}). But those who were affected by a thrombocytopenic event had a higher relative frequency of IgG trough-level under 7 g/l in serum compared to patients without a thrombocytopenic event (OR 0.75, 95% CI 0.12--7.03; *p* \< 0.0001) (Figure [4](#F4){ref-type="fig"}). This indicates that a low IgG level is a key factor for the development of thrombocytopenia. In addition, there was no patient affected by autoimmune hemolytic anemia or autoimmune neutropenia during the 5-year observation period.

![Replacement therapy among autoimmune thrombocytopenia (AITP) patients related to IgG through levels. Number of patients with AITP bouts under intravenous immunoglobulin (IVIG) (*n* = 7) and under SCIG (*n* = 8). Box plot diagrams represent the lower quartile, the median and the upper quartile, while the whiskers show the 10th and 90th percentiles. Differences were compared by the Mann--Whitney *U*-test. No differences were observed, *p* = 0.4634. *p* is considered significant when \< 0.05.](fimmu-09-01656-g003){#F3}

![Occurrence of autoimmune thrombocytopenia (AITP) related to IgG through levels. Patients with AITP (*n* = 15) and those without bouts (*n* = 45) are depicted in box plot diagrams. Box plots show the lower quartile, the median and the upper quartile, while the whiskers show the 10th and 90th percentiles. A significant difference was observed among patients with through levels under 7 g/l. From the AITP group 12 patients (80%) had through levels below this cut point, while from the non-AITP group 44 patients (97.7%) where above 7 g/l. Group comparisons were performed by the Mann--Whitney *U* test. *p* is considered significant when \<0.05.](fimmu-09-01656-g004){#F4}

Discussion {#S4}
==========

Given that IGRT is increasingly applied subcutaneously; we expected that this study could help to understand better the role of available options of IGRT in patients with both AITP and CVID in a clinical setting. The German Registry for PID found out that 73% of patients with PID are receiving SCIG and 27% are under IVIG replacement ([@B7]).

In this cohort study, the groups differed at baseline in participant characteristics: gender, splenectomy status, immunomodulation, and replacement therapy. The comparability of the groups was questioned by counting the occurrence of influencing factors. We found no statistically significant differences related to gender. Therapeutic options for AITP include steroids, immunosuppressant, and splenectomy ([@B8], [@B9]). However, none of these factors seem to have influenced the IGRT administration route.

Antibodies to thrombocytes were not tested for all patients; the measurement of platelet-associated IgG for the diagnosis of ITP is published to have a sensitivity around 90%, but its specificity is only 27%; hence, the positive predictive value is only \<50% and its diagnostic value is poor. While the measurement of specific platelet glycoprotein antibodies has higher specificity (78--92%), its diagnostic value is limited by low sensitivity (49--66%) with a positive predictive value of 80--83% ([@B10]). We differentiated hypersplenism from AITP according to the clinical observation of the platelets kinetics: in AITP the drop of platelets is quick, while hypersplenism develops more slowly in CVID and usually leads to a gradual reduction in platelet counts.

When comparing IVIG vs. SCIG replacement with the occurrence of AITP events, we did not find a different incidence of thrombocytopenic events between groups. Although our sample size is limited, our data do not give a signal that SCIG is less safe than IVIG for patients with CVID and concomitant autoimmune cytopenia.

It has been established that target through serum IgG, achieved by either intravenous or subcutaneous route varies and the goal is to prevent infections ([@B1], [@B11]).

Trough levels have not been previously related to thrombocytopenic events. Our study suggests IgG trough-levels under 7 g/l point to be a key factor for development of thrombocytopenia.

This study is limited by its statistical power and its retrospective design. Based on statistical tests we analyzed differences between groups and, therefore, only controlled for type I errors. Due to the limited sample size there is possibly a high risk of type II errors, for which our tests did not control. Hence, further investigations are necessary. This should be addressed in the coming years by collecting prospective data on the above identified 60 patients.

In summary, we did not find a higher occurrence of thrombocytopenic events in CVID patients who received SCIG, compared to CVID patients who had an intravenous application of IgG, but we identified a low IgG through level as a risk factor for ITP bouts.
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